伊布迪拉斯特在中风后炎症中具有免疫调节和血管保护作用
Sima Abbasi-Habashi1, Yonglie Ma2, Glen C Jickling3
1Neurochemical Research Unit, Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 12, 2025
概括
在小鼠中,Ibudilast治疗改善了血液流动,并在缺血性中风后减少了中性粒细胞停滞. 这种疗法显著减少了心脏病发作的大小,突出了其在急性缺血性中风治疗中的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 缺血性中风会导致持续的微血管功能障碍和炎症,即使在大血管成功重新开放后,也会阻碍恢复.
- 中性粒细胞粘附和毛细血管停滞是中风后微血管衰竭的关键因素.
- 在中风后,PDE3/4抑制剂Ibudilast对微血管流量和中性粒细胞阻塞的影响尚不清楚.
研究的目的:
- 为了研究Ibudilast对脑输液,中性粒细胞动态和心脏病发作大小在缺血性中风的小鼠模型的影响.
- 评估Ibudilast在不同年龄组和性别的疗效,反映临床变异性.
- 为了确定Ibudilast是否减轻了中性粒细胞介导的微血管阻塞.
主要方法:
- 在年轻和年长的雄性和雌性C57BL/6小鼠中,过渡性中脑动脉封闭 (MCAO) 模型.
- 在封闭后30分钟和6小时内内注射Ibudilast (30mg/kg).
- 在体成像3和24小时后再输血 (PR) 评估血液动力学,中性粒细胞的行为和心脏病发作量.
主要成果:
- 伊布迪拉斯特治疗保留了血管直径,保持了流速,恢复了红细胞流量,并在表面和毛细血管网络中增强了 perfusion.
- 微血管参数的改善在年轻和雌性小鼠中最为显著.
- 中性粒细胞粘附和毛细血管停滞减少,中性粒细胞停滞和血管流量受损之间的相关性在Ibudilast治疗的小鼠中被废除.
- 与车辆对照组相比,在24hPR时观察到心脏病发作体积显著减少 (> 50%).
结论:
- 在缺血性中风后,ibudilast有效地保持了微血管的完整性和功能.
- 该药物减少了中性粒细胞介导的微血管阻塞,这是导致不良结果的关键因素.
- 伊布迪拉斯特在减少心脏病发作大小和改善急性缺血性中风的恢复方面显示出显著的治疗潜力.
相关概念视频
01:30Inflammatory Response I: Vascular and Cellular
16.0K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
16.0K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
01:28Inflammatory Response
16.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
16.0K